Corpus
Pascal
Racine
Corpus
Checkpoint
Pascal
Racine
Pascal
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur le thulium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation

Identifieur interne : 000336 ( Pascal/Corpus ); précédent : 000335; suivant : 000337

70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation

Auteurs : Thorsten Bach ; Nina Huck ; Felix Wezel ; Axel H Cker ; Andreas J. Gross ; Maurice Stephan Michel ; Alexis Te

Source :

RBID : Pascal:10-0372794

Descripteurs français

English descriptors

Abstract

OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 1464-4096
A03   1    @0 BJU int. : (Print)
A05       @2 106
A06       @2 3
A08 01  1  ENG  @1 70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation
A11 01  1    @1 BACH (Thorsten)
A11 02  1    @1 HUCK (Nina)
A11 03  1    @1 WEZEL (Felix)
A11 04  1    @1 HÄCKER (Axel)
A11 05  1    @1 GROSS (Andreas J.)
A11 06  1    @1 STEPHAN MICHEL (Maurice)
A11 07  1    @1 TE (Alexis)
A14 01      @1 Department of Urology, University Medical Centre Mannheim @2 Mannheim @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut.
A14 02      @1 Department of Urology, Asklepios Hospital Barmbek @2 Hamburg @3 DEU @Z 1 aut. @Z 5 aut.
A14 03      @1 Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital @2 New York, NY @3 USA @Z 7 aut.
A20       @1 368-372
A21       @1 2010
A23 01      @0 ENG
A43 01      @1 INIST @2 1050 @5 354000191701750120
A44       @0 0000 @1 © 2010 INIST-CNRS. All rights reserved.
A45       @0 19 ref.
A47 01  1    @0 10-0372794
A60       @1 P
A61       @0 A
A64 01  1    @0 BJU international : (Papier)
A66 01      @0 GBR
C01 01    ENG  @0 OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.
C02 01  X    @0 002B14D02
C02 02  X    @0 002B20B02
C03 01  X  FRE  @0 Adénome de la prostate @2 NM @5 01
C03 01  X  ENG  @0 Benign prostatic hyperplasia @2 NM @5 01
C03 01  X  SPA  @0 Hiperplasia prostática benigna @2 NM @5 01
C03 02  X  FRE  @0 Etude comparative @5 02
C03 02  X  ENG  @0 Comparative study @5 02
C03 02  X  SPA  @0 Estudio comparativo @5 02
C03 03  X  FRE  @0 Thulium @2 NC @5 03
C03 03  X  ENG  @0 Thulium @2 NC @5 03
C03 03  X  SPA  @0 Tulio @2 NC @5 03
C03 04  X  FRE  @0 Yttrium @2 NC @5 05
C03 04  X  ENG  @0 Yttrium @2 NC @5 05
C03 04  X  SPA  @0 Ytrio @2 NC @5 05
C03 05  X  FRE  @0 Aluminium @2 NC @2 FR @2 FX @5 06
C03 05  X  ENG  @0 Aluminium @2 NC @2 FR @2 FX @5 06
C03 05  X  SPA  @0 Aluminio @2 NC @2 FR @2 FX @5 06
C03 06  X  FRE  @0 Onde entretenue @5 08
C03 06  X  ENG  @0 Continuous wave @5 08
C03 06  X  SPA  @0 Onda continua @5 08
C03 07  X  FRE  @0 Ex vivo @5 09
C03 07  X  ENG  @0 Ex vivo @5 09
C03 07  X  SPA  @0 Ex vivo @5 09
C03 08  X  FRE  @0 Evaluation @5 11
C03 08  X  ENG  @0 Evaluation @5 11
C03 08  X  SPA  @0 Evaluación @5 11
C03 09  X  FRE  @0 Prostate @5 12
C03 09  X  ENG  @0 Prostate @5 12
C03 09  X  SPA  @0 Prostata @5 12
C03 10  X  FRE  @0 Tissu @5 17
C03 10  X  ENG  @0 Tissue @5 17
C03 10  X  SPA  @0 Tejido @5 17
C03 11  X  FRE  @0 Ablation @5 18
C03 11  X  ENG  @0 Ablation @5 18
C03 11  X  SPA  @0 Ablación @5 18
C03 12  X  FRE  @0 Coagulation sanguine @5 19
C03 12  X  ENG  @0 Blood coagulation @5 19
C03 12  X  SPA  @0 Coagulación sanguínea @5 19
C03 13  X  FRE  @0 Laser @5 20
C03 13  X  ENG  @0 Laser @5 20
C03 13  X  SPA  @0 Láser @5 20
C03 14  X  FRE  @0 Néphrologie @5 21
C03 14  X  ENG  @0 Nephrology @5 21
C03 14  X  SPA  @0 Nefrología @5 21
C03 15  X  FRE  @0 Urologie @5 22
C03 15  X  ENG  @0 Urology @5 22
C03 15  X  SPA  @0 Urología @5 22
C03 16  X  FRE  @0 Traitement laser @4 INC @5 86
C07 01  X  FRE  @0 Pathologie de l'appareil génital mâle @5 37
C07 01  X  ENG  @0 Male genital diseases @5 37
C07 01  X  SPA  @0 Aparato genital macho patología @5 37
C07 02  X  FRE  @0 Pathologie de l'appareil urinaire @5 38
C07 02  X  ENG  @0 Urinary system disease @5 38
C07 02  X  SPA  @0 Aparato urinario patología @5 38
C07 03  X  FRE  @0 Tumeur bénigne @5 39
C07 03  X  ENG  @0 Benign neoplasm @5 39
C07 03  X  SPA  @0 Tumor benigno @5 39
C07 04  X  FRE  @0 Pathologie de la prostate @5 40
C07 04  X  ENG  @0 Prostate disease @5 40
C07 04  X  SPA  @0 Prostata patología @5 40
C07 05  X  FRE  @0 Appareil urogénital @5 41
C07 05  X  ENG  @0 Urogenital system @5 41
C07 05  X  SPA  @0 Aparato urogenital @5 41
N21       @1 242
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 10-0372794 INIST
ET : 70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation
AU : BACH (Thorsten); HUCK (Nina); WEZEL (Felix); HÄCKER (Axel); GROSS (Andreas J.); STEPHAN MICHEL (Maurice); TE (Alexis)
AF : Department of Urology, University Medical Centre Mannheim/Mannheim/Allemagne (1 aut., 2 aut., 3 aut., 4 aut., 6 aut.); Department of Urology, Asklepios Hospital Barmbek/Hamburg/Allemagne (1 aut., 5 aut.); Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital/New York, NY/Etats-Unis (7 aut.)
DT : Publication en série; Niveau analytique
SO : BJU international : (Papier); ISSN 1464-4096; Royaume-Uni; Da. 2010; Vol. 106; No. 3; Pp. 368-372; Bibl. 19 ref.
LA : Anglais
EA : OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.
CC : 002B14D02; 002B20B02
FD : Adénome de la prostate; Etude comparative; Thulium; Yttrium; Aluminium; Onde entretenue; Ex vivo; Evaluation; Prostate; Tissu; Ablation; Coagulation sanguine; Laser; Néphrologie; Urologie; Traitement laser
FG : Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur bénigne; Pathologie de la prostate; Appareil urogénital
ED : Benign prostatic hyperplasia; Comparative study; Thulium; Yttrium; Aluminium; Continuous wave; Ex vivo; Evaluation; Prostate; Tissue; Ablation; Blood coagulation; Laser; Nephrology; Urology
EG : Male genital diseases; Urinary system disease; Benign neoplasm; Prostate disease; Urogenital system
SD : Hiperplasia prostática benigna; Estudio comparativo; Tulio; Ytrio; Aluminio; Onda continua; Ex vivo; Evaluación; Prostata; Tejido; Ablación; Coagulación sanguínea; Láser; Nefrología; Urología
LO : INIST-1050.354000191701750120
ID : 10-0372794

Links to Exploration step

Pascal:10-0372794

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation</title>
<author>
<name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Huck, Nina" sort="Huck, Nina" uniqKey="Huck N" first="Nina" last="Huck">Nina Huck</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Wezel, Felix" sort="Wezel, Felix" uniqKey="Wezel F" first="Felix" last="Wezel">Felix Wezel</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="H Cker, Axel" sort="H Cker, Axel" uniqKey="H Cker A" first="Axel" last="H Cker">Axel H Cker</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Stephan Michel, Maurice" sort="Stephan Michel, Maurice" uniqKey="Stephan Michel M" first="Maurice" last="Stephan Michel">Maurice Stephan Michel</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Te, Alexis" sort="Te, Alexis" uniqKey="Te A" first="Alexis" last="Te">Alexis Te</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">10-0372794</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0372794 INIST</idno>
<idno type="RBID">Pascal:10-0372794</idno>
<idno type="wicri:Area/Pascal/Corpus">000336</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation</title>
<author>
<name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Huck, Nina" sort="Huck, Nina" uniqKey="Huck N" first="Nina" last="Huck">Nina Huck</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Wezel, Felix" sort="Wezel, Felix" uniqKey="Wezel F" first="Felix" last="Wezel">Felix Wezel</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="H Cker, Axel" sort="H Cker, Axel" uniqKey="H Cker A" first="Axel" last="H Cker">Axel H Cker</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Stephan Michel, Maurice" sort="Stephan Michel, Maurice" uniqKey="Stephan Michel M" first="Maurice" last="Stephan Michel">Maurice Stephan Michel</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Te, Alexis" sort="Te, Alexis" uniqKey="Te A" first="Alexis" last="Te">Alexis Te</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">BJU international : (Papier)</title>
<title level="j" type="abbreviated">BJU int. : (Print)</title>
<idno type="ISSN">1464-4096</idno>
<imprint>
<date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">BJU international : (Papier)</title>
<title level="j" type="abbreviated">BJU int. : (Print)</title>
<idno type="ISSN">1464-4096</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Ablation</term>
<term>Aluminium</term>
<term>Benign prostatic hyperplasia</term>
<term>Blood coagulation</term>
<term>Comparative study</term>
<term>Continuous wave</term>
<term>Evaluation</term>
<term>Ex vivo</term>
<term>Laser</term>
<term>Nephrology</term>
<term>Prostate</term>
<term>Thulium</term>
<term>Tissue</term>
<term>Urology</term>
<term>Yttrium</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Adénome de la prostate</term>
<term>Etude comparative</term>
<term>Thulium</term>
<term>Yttrium</term>
<term>Aluminium</term>
<term>Onde entretenue</term>
<term>Ex vivo</term>
<term>Evaluation</term>
<term>Prostate</term>
<term>Tissu</term>
<term>Ablation</term>
<term>Coagulation sanguine</term>
<term>Laser</term>
<term>Néphrologie</term>
<term>Urologie</term>
<term>Traitement laser</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>1464-4096</s0>
</fA01>
<fA03 i2="1">
<s0>BJU int. : (Print)</s0>
</fA03>
<fA05>
<s2>106</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>BACH (Thorsten)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>HUCK (Nina)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>WEZEL (Felix)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>HÄCKER (Axel)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>GROSS (Andreas J.)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>STEPHAN MICHEL (Maurice)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>TE (Alexis)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Urology, University Medical Centre Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20>
<s1>368-372</s1>
</fA20>
<fA21>
<s1>2010</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>1050</s2>
<s5>354000191701750120</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>10-0372794</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>BJU international : (Papier)</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B14D02</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Adénome de la prostate</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Benign prostatic hyperplasia</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Hiperplasia prostática benigna</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Etude comparative</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Comparative study</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Estudio comparativo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Thulium</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Thulium</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Tulio</s0>
<s2>NC</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Yttrium</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Yttrium</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Ytrio</s0>
<s2>NC</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Aluminium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Aluminium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Aluminio</s0>
<s2>NC</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Onde entretenue</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Continuous wave</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Onda continua</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Ex vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Ex vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Ex vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Evaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Evaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Evaluación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Prostate</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Prostate</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Prostata</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Tissu</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Tissue</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Tejido</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Ablation</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Ablation</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Ablación</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Coagulation sanguine</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Blood coagulation</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Coagulación sanguínea</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Laser</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Laser</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Láser</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Néphrologie</s0>
<s5>21</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Nephrology</s0>
<s5>21</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Nefrología</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Urologie</s0>
<s5>22</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Urology</s0>
<s5>22</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Urología</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Traitement laser</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Pathologie de l'appareil génital mâle</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Male genital diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Aparato genital macho patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Pathologie de l'appareil urinaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Urinary system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Aparato urinario patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Tumeur bénigne</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Benign neoplasm</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Tumor benigno</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie de la prostate</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Prostate disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Prostata patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Appareil urogénital</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Urogenital system</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Aparato urogenital</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>242</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 10-0372794 INIST</NO>
<ET>70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation</ET>
<AU>BACH (Thorsten); HUCK (Nina); WEZEL (Felix); HÄCKER (Axel); GROSS (Andreas J.); STEPHAN MICHEL (Maurice); TE (Alexis)</AU>
<AF>Department of Urology, University Medical Centre Mannheim/Mannheim/Allemagne (1 aut., 2 aut., 3 aut., 4 aut., 6 aut.); Department of Urology, Asklepios Hospital Barmbek/Hamburg/Allemagne (1 aut., 5 aut.); Urology, Weill Medical College of Cornell University and New York Presbyterian Hospital/New York, NY/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>BJU international : (Papier); ISSN 1464-4096; Royaume-Uni; Da. 2010; Vol. 106; No. 3; Pp. 368-372; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>OBJECTIVE To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. MATERIALS AND METHODS The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 μm continuous-wave Tm-YAG laser. The energy was delivered using a 550-μm and an 800-μm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histological evaluation. After staining (haematoxylin and eosin, H&tE; and NADH) of the specimen, the coagulation zone and depth of the necrotic tissue layer were measured. RESULTS With increased power output, the mean (SD) rate of vaporization of tissue increased, from 9.80 (3.03) g/10 min at 70 W to 16.41 (5.2) g/ 10 min at 120 W using the 550 μm fibre. The total amount of ablated tissue using the 800 μm fibre was lower than with the 550 μm fibre. With increasing power output the bleeding rate remained stable in either group. Tissue penetration remained shallow, even with increasing power output. In contrast to H&tE staining, where the coagulation zone was measured, NADH staining showed an inner zone of necrotic tissue, again with no difference between the 70- and the 120-W Tm-YAG. CONCLUSION The 120-W Tm-YAG offers significantly higher ablation rates than the 70-W device, and despite the increased rate of ablation with the 120-W Tm-YAG, the bleeding rate and depth of tissue penetration were comparable to those using the 70-W device.</EA>
<CC>002B14D02; 002B20B02</CC>
<FD>Adénome de la prostate; Etude comparative; Thulium; Yttrium; Aluminium; Onde entretenue; Ex vivo; Evaluation; Prostate; Tissu; Ablation; Coagulation sanguine; Laser; Néphrologie; Urologie; Traitement laser</FD>
<FG>Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur bénigne; Pathologie de la prostate; Appareil urogénital</FG>
<ED>Benign prostatic hyperplasia; Comparative study; Thulium; Yttrium; Aluminium; Continuous wave; Ex vivo; Evaluation; Prostate; Tissue; Ablation; Blood coagulation; Laser; Nephrology; Urology</ED>
<EG>Male genital diseases; Urinary system disease; Benign neoplasm; Prostate disease; Urogenital system</EG>
<SD>Hiperplasia prostática benigna; Estudio comparativo; Tulio; Ytrio; Aluminio; Onda continua; Ex vivo; Evaluación; Prostata; Tejido; Ablación; Coagulación sanguínea; Láser; Nefrología; Urología</SD>
<LO>INIST-1050.354000191701750120</LO>
<ID>10-0372794</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pascal/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000336 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pascal/Corpus/biblio.hfd -nk 000336 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    Pascal
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0372794
   |texte=   70 vs 120 W thulium:yttrium-aluminium-garnet 2 μm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluation
}}
Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024